Cargando…

miR‐30e‐5p as predictor of generalization in ocular myasthenia gravis

OBJECTIVE: To determine a predictive factor for the risk of conversion from ocular myasthenia gravis (OMG) to generalized MG (GMG) in a prospective study. METHODS: RNA was isolated from serum samples and detection of microRNA (miRNA) expression analyzed with qPCR. In the discovery set, 179 human miR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabre, Liis, Maddison, Paul, Wong, Sui H., Sadalage, Girija, Ambrose, Philip A., Plant, Gordon T., Punga, Anna R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389736/ https://www.ncbi.nlm.nih.gov/pubmed/30847357 http://dx.doi.org/10.1002/acn3.692

Ejemplares similares

Thymectomy lowers the myasthenia gravis biomarker miR-150-5p
por: Molin, Carl Johan, et al.
Publicado: (2018)

Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine
por: Sabre, Liis, et al.
Publicado: (2020)

Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries
por: Sabre, Liis, et al.
Publicado: (2017)

Comparison of Clinical Manifestations between Patients with Ocular Myasthenia Gravis and Generalized Myasthenia Gravis
por: Roh, Hyun Seok, et al.
Publicado: (2011)

Sotalol‐induced generalized and ocular myasthenia gravis
por: Sharifkazemi, Mohammadbagher, et al.
Publicado: (2019)

Initial Repetitive Nerve Stimulation Test Predicts Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Prognostic factors for conversion to generalization in ocular myasthenia gravis
por: Witthayaweerasak, Juthamat, et al.
Publicado: (2021)

Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020)

Epidemiology of Myasthenia Gravis in Sweden 2006–2016
por: Westerberg, Elisabet, et al.
Publicado: (2020)

Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis
por: Townsel, Courtney, et al.
Publicado: (2016)

Ocular myasthenia gravis: A review
por: Nair, Akshay Gopinathan, et al.
Publicado: (2014)

Update on ocular myasthenia gravis in Taiwan
por: Lin, Chao-Wen, et al.
Publicado: (2018)

Myasthenia Gravis and Physical Exercise: A Novel Paradigm
por: O'Connor, Laura, et al.
Publicado: (2020)

Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker
por: Punga, Tanel, et al.
Publicado: (2014)

Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p
por: Beretta, Francesca, et al.
Publicado: (2022)

Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients
por: Molin, Carl Johan, et al.
Publicado: (2017)

Frontalis sling procedure for ocular myasthenia gravis
por: Asamura, Shinichi, et al.
Publicado: (2012)

Ocular myasthenia gravis in a setting of thyrotoxicosis
por: Chhabra, Sarabjeet, et al.
Publicado: (2013)

Autoantibodies in Japanese patients with ocular myasthenia gravis
por: Nagaishi, Akiko, et al.
Publicado: (2020)

Commentary: Ocular myasthenia gravis: Interpreting the investigations
por: Nair, Akshay Gopinathan
Publicado: (2022)

Ocular Myasthenia Gravis: A Current Overview
por: Behbehani, Raed
Publicado: (2023)

Ophthalmologic clinical features of ocular myasthenia gravis
por: Kim, Do-Hyung, et al.
Publicado: (2023)

Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol
por: Fang, Clarissa E H, et al.
Publicado: (2022)

Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset
por: Zhao, Sijia, et al.
Publicado: (2022)

Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China
por: Ding, Jiaqi, et al.
Publicado: (2020)

Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis
por: Ruan, Zhe, et al.
Publicado: (2022)

Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis
por: Bi, Zhuajin, et al.
Publicado: (2022)

Clinical predictors for the prognosis of myasthenia gravis
por: Wang, Lili, et al.
Publicado: (2017)

Efficacy of Gaze Photographs in Diagnosing Ocular Myasthenia Gravis
por: Ahn, Jeeyun, et al.
Publicado: (2018)

Local use of dexamethasone in the treatment of ocular myasthenia gravis
por: Shi, Minghua, et al.
Publicado: (2020)

AZD-1222: Ocular myasthenia gravis: case report
Publicado: (2022)

Diagnostic yields and clinical features of ocular myasthenia gravis
por: Kim, Hyuna, et al.
Publicado: (2021)

Immunotherapy for ocular myasthenia gravis: an observational study in Japan
por: Narita, Tomoko, et al.
Publicado: (2023)

Clinical Signs in Neuro-Ophthalmology: Eye Signs in Myasthenia Gravis
por: Wong, Sui Hsien
Publicado: (2022)

Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular Symptoms
por: Nishimoto, Yoshinori, et al.
Publicado: (2011)

Characterization of patients with ocular myasthenia gravis — A case series
por: Karni, Arnon, et al.
Publicado: (2016)

Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases
por: Europa, Tarin A., et al.
Publicado: (2022)

Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis
por: Zhang, Jinwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rut8ls7t4v4euiq51jkbvt1ei3